Promoter methylation profile of GSTP1 and RASSF1A in prostate cancerand benign hyperplasia in Vietnamese men
Autor: | Dieu Linh Vuong, Bich Thuan Ta, Van To Ta, Thi Thuong Lan Vo, Quynh Uyen Nguyen |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
0301 basic medicine endocrine system Prostatic Hyperplasia urologic and male genital diseases Southeast asian 03 medical and health sciences Prostate cancer GSTP1 0302 clinical medicine Prostate medicine Humans Promoter Regions Genetic neoplasms business.industry GSTP1 methylation-specific polymerase chain reaction RASSF1A Tumor Suppressor Proteins Prostatic Neoplasms General Medicine Methylation DNA Methylation Hyperplasia medicine.disease 030104 developmental biology medicine.anatomical_structure Glutathione S-Transferase pi 030220 oncology & carcinogenesis DNA methylation Cancer research Biomarker (medicine) business |
Zdroj: | Volume: 46, Issue: 1 228-235 Turkish Journal of Medical Sciences |
ISSN: | 1303-6165 1300-0144 |
Popis: | Background/aim: The GSTP1 and RASSF1A methylations that were considered as prostate cancer-specific molecular biomarkers have been extensively reported in Western/American patients with prostate cancer but are rarely reported in Southeast Asian patients. In the present study, the methylation status of the GSTP1 and RASSF1A promoters was evaluated in prostate cancer (PCa) and benign prostate hyperplasia (BPH) tissues from Vietnamese men. Materials and methods: The accuracy of methylation-specific polymerase chain reaction (MSP) was validated to analyze the methylation pattern of GSTP1 and RASSF1A in 59 PCa and 37 BPH patients, respectively. The methylation status was confirmed by the sequencing of cloned MSP products. The association between methylation status and the clinical and pathological parameters of tumors was statistically analyzed. Results: The methylation of GSTP1 and RASSF1A was detected in 39/59 and 19/59 PCa patients and in 4/37 and 10/37 BPH patients, respectively. The methylation frequency of GSTP1 was significantly associated with PCa (P < 0.01). The RASSF1A methylation frequency (32.2%) observed in the study was lower relative to that detected in other populations. Conclusions: GSTP1 and RASSF1A methylation was accurately detected using the validated MSP method and can be used as a biomarker to diagnose prostate cancer. |
Databáze: | OpenAIRE |
Externí odkaz: |